March 9 Deadline Set for Investors to Seek Lead Role in Ardent Health Securities Class Action

Overview

• The putative class action, captioned Postiwala v. Ardent Health, Inc., No. 3:26-cv-00022, is pending in the U.S. District Court for the Middle District of Tennessee.
• Investors who bought Ardent Health securities between July 18, 2024 and November 12, 2025 are invited to seek appointment as lead plaintiff by March 9, 2026.
• The complaint alleges Ardent touted detailed historical collection reviews while actually using a 180‑day reserve policy that delayed loss recognition on uncollectible accounts.
• Ardent disclosed on November 12, 2025 a $43 million revenue reduction from hindsight collection evaluations and a $54 million increase to professional liability reserves, after which the stock fell more than 33%.
• Claims are brought under Sections 10(b) and 20(a) of the Exchange Act, with multiple firms including Bleichmar Fonti & Auld, Rosen Law Firm, and Glancy Prongay & Murray soliciting class members on a contingency basis.